Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Photoactivatable Materials for Versatile Single-Cell Patterning Based on the Photocaging of Cell-Anchoring Moieties through Lipid Self-Assembly.

Journal of the American Chemical Society·2022

Same author

Natural adjuvants (<i>PC</i> and <i>G2</i>) induce activated natural killer cells with NKG2D expression and cytotoxic properties in colorectal cancer.

Gastroenterology and hepatology from bed to bench·2022

Same author

Autologous Natural Killer Cell-enrichment for Immune Cell Therapy: Preclinical Setting Phase, Shiraz Experience.

Iranian journal of allergy, asthma, and immunology·2021

Same author

Facile Fabrication of Thin-Bottom Round-Well Plates Using the Deformation of PDMS Molds and Their Application for Single-Cell PCR.

Micromachines·2020

Same author

Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.

Cancer science·2020

Same author

Cell Energy: A New Hypothesis in Decoding Cancer Evolution.

Archives of Iranian medicine·2019

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

[Gene therapy for myeloid leukemia].

¹Department of Medical Oncology, National Cancer Center Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|October 29, 2009

Summary

This summary is machine-generated.

Gene therapy using herpes simplex virus-thymidine kinase (HSV-TK) modified T cells shows promise for myeloid leukemia treatment. Advanced clinical trials focus on T cell add-back and donor lymphocyte infusions post-transplant.

More Related Videos

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Jun 19, 2026

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Area of Science:

Immunotherapy
Gene Therapy
Hematologic Malignancies

Context:

Myeloid leukemia treatment landscape.
Allogeneic stem cell transplantation (allo-SCT) as a curative approach.
Need for improved post-transplant outcomes and relapse prevention.

Purpose:

To review gene therapy strategies utilizing herpes simplex virus-thymidine kinase (HSV-TK) gene-modified T lymphocytes in allo-SCT for myeloid leukemia.
To discuss the current status of advanced clinical trials involving T cell add-back and donor lymphocyte infusions.
To provide an overview of other emerging gene therapy approaches, including cytokine gene-modified CML-DC and T cell receptor (TCR) gene-modified T lymphocytes.

Summary:

Focus on T cell depleted haplo-identical transplantation with HSV-TK gene-modified T cell add-back.
Highlights donor lymphocyte infusion using HSV-TK gene-modified T cells for patients experiencing recurrence post-allo-SCT.
Explores alternative gene therapies: cytokine gene-modified CML-DC and TCR gene-modified T lymphocytes for myeloid leukemia.

Impact:

Potential to improve efficacy and reduce relapse rates in myeloid leukemia patients undergoing allo-SCT.
Advances the field of adoptive immunotherapy for hematologic malignancies.
Provides insights into the future directions of gene-engineered T cell therapies.